Single-cell and clinical analyses reveal elevated HAX1 expression and cell-cycle-associated programs during metastatic progression of lung adenocarcinoma, particularly in brain metastasis
Abstract
IntroductionMetastatic dissemination is a major determinant of poor outcome in lung adenocarcinoma (LUAD). However, molecular features associated with distinct metastatic states, particularly lymph node and brain metastases, remain incompletely defined. We investigated the relationship between HAX1 and LUAD metastatic progression.MethodsWe reanalyzed publicly available single-cell RNA-sequencing data from GSE131907 to characterize HAX1 expression and associated transcriptional programs across normal lung, primary LUAD, advanced tumors, metastatic lymph nodes (mLN), and brain metastases. Findings were validated using additional public datasets from GEO and TCGA, including the independent single-cell dataset GSE69405. Clinical LUAD specimens were analyzed to assess HAX1 protein expression and its clinicopathological associations. Functional validation was performed in A549 and H1975 cells, and tumor growth was assessed using an A549-derived subcutaneous xenograft model.ResultsHAX1 expression and the proportion of HAX1-positive epithelial cells increased across LUAD disease states and were significantly enriched in mLN and brain-metastatic epithelial populations compared with primary tumors. In a 125-patient clinical cohort, high HAX1 expression was associated with lymph node metastasis, advanced stage, and shorter overall survival, and remained independently associated with lymph node metastasis after adjustment for T stage (OR = 2.581, 95% CI 1.161–5.742; P = 0.020). An independent single-cell dataset further confirmed elevated HAX1 expression in brain-metastatic LUAD cells. HAX1-associated transcriptional programs converged on E2F, MYC, MTORC1, DNA replication, and cell-cycle signatures, whereas brain-metastatic epithelial cells additionally exhibited mitochondrial and translational programs. Integrated analyses identified UBE2S, PITX1, GGH, and PDCD2L as HAX1-associated candidates.EPIC and TIMER analyses consistently showed inverse correlations between HAX1 expression and estimated B-cell, CD4+ T-cell, CD8+ T-cell, and macrophage abundance. HAX1 knockdown also reduced cell viability, increased the G0/G1-phase fraction and decreased the S-phase fraction, reduced G1/S-related protein levels and PI3K/AKT signaling, and inhibited subcutaneous xenograft growth.ConclusionHAX1 is closely associated with metastatic progression of LUAD, with strong clinical evidence for lymph node involvement and reproducible enrichment in brain-metastatic epithelial cells. Its associations with cell-cycle programs and immune cell infiltration, together with its functional role in G1/S progression, support further investigation of HAX1 in metastatic adaptation and tumor–immune interactions.
Related
- Associated Bacteria, Particularly Mucilaginibacter Species, Inhibit Sheath Formation in Nostoc commune
- Genomic correlates of metastatic competence and progression in human melanoma
- Case Report: Durable complete response to dual immune checkpoint blockade and EGFR inhibition in microsatellite-stable metastatic duodenal adenocarcinoma
- Novel two-stage deep learning-based approach applied to gene expression data pertaining to esophageal adenocarcinoma boosting biological knowledge discovery
- An immunosuppression imaging gauge prospectively predicts metastatic progression and immunotherapy resistance in breast cancer
BibTeX
@article{xie2026singlecell,
title = {{Single-cell and clinical analyses reveal elevated HAX1 expression and cell-cycle-associated programs during metastatic progression of lung adenocarcinoma, particularly in brain metastasis}},
author = {Tian Xie and Wei He and Zhihao Li and Hao Dong and Xingyi Li and Chenxu Liu and Chongjun Zhong and Haijun Zhang and Xiaolong Liu and Yifan Zheng},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1976012},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1976012},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Single-cell and clinical analyses reveal elevated HAX1 expression and cell-cycle-associated programs during metastatic progression of lung adenocarcinoma, particularly in brain metastasis
AU - Tian Xie
AU - Wei He
AU - Zhihao Li
AU - Hao Dong
AU - Xingyi Li
AU - Chenxu Liu
AU - Chongjun Zhong
AU - Haijun Zhang
AU - Xiaolong Liu
AU - Yifan Zheng
PY - 2026
DA - 2026/11/11
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1976012
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1976012
AB - IntroductionMetastatic dissemination is a major determinant of poor outcome in lung adenocarcinoma (LUAD). However, molecular features associated with distinct metastatic states, particularly lymph node and brain metastases, remain incompletely defined. We investigated the relationship between HAX1 and LUAD metastatic progression.MethodsWe reanalyzed publicly available single-cell RNA-sequencing data from GSE131907 to characterize HAX1 expression and associated transcriptional programs across normal lung, primary LUAD, advanced tumors, metastatic lymph nodes (mLN), and brain metastases. Findings were validated using additional public datasets from GEO and TCGA, including the independent single-cell dataset GSE69405. Clinical LUAD specimens were analyzed to assess HAX1 protein expression and its clinicopathological associations. Functional validation was performed in A549 and H1975 cells, and tumor growth was assessed using an A549-derived subcutaneous xenograft model.ResultsHAX1 expression and the proportion of HAX1-positive epithelial cells increased across LUAD disease states and were significantly enriched in mLN and brain-metastatic epithelial populations compared with primary tumors. In a 125-patient clinical cohort, high HAX1 expression was associated with lymph node metastasis, advanced stage, and shorter overall survival, and remained independently associated with lymph node metastasis after adjustment for T stage (OR = 2.581, 95% CI 1.161–5.742; P = 0.020). An independent single-cell dataset further confirmed elevated HAX1 expression in brain-metastatic LUAD cells. HAX1-associated transcriptional programs converged on E2F, MYC, MTORC1, DNA replication, and cell-cycle signatures, whereas brain-metastatic epithelial cells additionally exhibited mitochondrial and translational programs. Integrated analyses identified UBE2S, PITX1, GGH, and PDCD2L as HAX1-associated candidates.EPIC and TIMER analyses consistently showed inverse correlations between HAX1 expression and estimated B-cell, CD4+ T-cell, CD8+ T-cell, and macrophage abundance. HAX1 knockdown also reduced cell viability, increased the G0/G1-phase fraction and decreased the S-phase fraction, reduced G1/S-related protein levels and PI3K/AKT signaling, and inhibited subcutaneous xenograft growth.ConclusionHAX1 is closely associated with metastatic progression of LUAD, with strong clinical evidence for lymph node involvement and reproducible enrichment in brain-metastatic epithelial cells. Its associations with cell-cycle programs and immune cell infiltration, together with its functional role in G1/S progression, support further investigation of HAX1 in metastatic adaptation and tumor–immune interactions.
SN - 1664-3224
ER -